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Background: Intra-tumor heterogeneity is a potential cause for failure of targeted therapy in gastric cancer, but the
extent of heterogeneity of established (HER2) or potential (EGFR, CCND1) target genes and prognostic gene
alterations (MYC) had not been systematically studied.
Methods: To study heterogeneity of these genes in a large patient cohort, a heterogeneity tissue microarray was
constructed containing 0.6 mm tissue cores from 9 different areas of the primary gastric cancers of 113 patients
and matched lymph node metastases from 61 of these patients. Dual color fluorescence in-situ hybridization was
performed to assess amplification of HER2, EGFR, CCND1 and MYC using established thresholds (ratio ≥ 2.0). Her2
immunohistochemistry (IHC) was performed in addition.
Results: Amplification was found in 17.4% of 109 interpretable cases for HER2, 6.4% for EGFR, 17.4% for CCND1, and
24.8% for MYC. HER2 amplification was strongly linked to protein overexpression by IHC in a spot-by-spot analysis
(p < 0.0001). Intra-tumor heterogeneity was found in the primary tumors of 9 of 19 (47.3%) cancers with HER2, 8 of
17 (47.0%) cancers with CCND1, 5 of 7 (71.4%) cancers with EGFR, and 23 of 27 (85.2%) cancers with MYC amplification.
Amplification heterogeneity was particularly frequent in case of low-level amplification (<10 gene copies). While the
amplification status was often different between metastases, unequivocal intra-tumor heterogeneity was not found in
individual metastases.
Conclusion: The data of our study demonstrate that heterogeneity is common for biomarkers in gastric cancer. Given
that both TMA tissue cores and clinical tumor biopsies analyze only a small fraction of the tumor bulk, it can be
concluded that such heterogeneity may potentially limit treatment decisions based on the analysis of a single clinical
cancer biopsy.
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Although its incidence and mortality is declining, gastric
adenocarcinoma remains the second most frequent
cause of cancer death worldwide [1-3]. Similar to most
other cancers, prognosis and therapeutic options depend
on clinicopathological parameters [4-6]. Surgery is the
only curative treatment, which is supplemented by
neoadjuvant and adjuvant (radio-) chemotherapy [7,8].
As our knowledge on the molecular biology of gastric
cancer increases rapidly, it can be hoped, that the* Correspondence: a.marx@uke.de
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unless otherwise stated.identification of molecular mechanisms driving cancer
aggressiveness, influencing response to specific chemo-
therapies, and representing direct targets for therapeutic
drugs will eventually enable a better treatment of our
patients.
Gene amplification is a prime mechanism of cancer
cells for overexpressing genes that are critical for their
survival and expansion. Determination of the amplifica-
tion status is thus often clinically relevant. For example,
MDM2 amplification is a diagnostic hallmark in lipo-
sarcoma [9], CCND1 amplification is a suspected pre-
dictor of resistance against hormone therapy in breast
cancer [10], MYC amplification is a strong prognostic
marker in breast cancer and other tumors [11], MYCNhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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neuroblastoma [12], and HER2/EGFR are established
therapeutic targets that are often overexpressed as a
consequence of gene amplification [13,14]. On a diag-
nostic level, gene amplification has the advantage that
the amplification level can be precisely measured on a
cell by cell basis by fluorescence in situ hybridization
(FISH). FISH analysis is unaffected by the (unavoid-
able) admixture of normal cells to cancer tissues and
FISH results are not altered by tissue processing
variations.
However, even if molecular methods work at the high-
est level of precision, diagnostic errors will occur in het-
erogeneous cancers. For practical purpose, the molecular
tumor status is generally determined on a small fraction
of the primary tumor, for example derived from a biopsy.
Such information will not always reflect the molecular
situation of the entire (heterogeneous) cancer mass. Mo-
lecular heterogeneity may not only lead to clones with
different aggressiveness within one cancer but also to
subpopulations with varying response to anti-cancer
drugs and thus be of utmost clinical significance. Never-
theless, even in most relevant cancer types and for
highly promising diagnostic and therapeutic molecules,
intra-tumor genetic heterogeneity is not analyzed in sys-
tematic studies to an extent that reflects the importance
of the topic.
Thus, the aim of our study was to gain deeper insight
in genomic heterogeneity in gastric cancer in a larger
scale. For this purpose, we selected 4 genes (HER2,
CCND1, MYC and EGFR) with established relevance for
gastric cancer, which were previously reported to be
amplified. Due to its analytical precision [13], FISH is
optimally suited for determining intra-tumor heterogen-
eity. In contrast to IHC analyses, FISH does not suffer
from false-negative findings since non-reactive tissues
can easily be identified by the absence of the FISH sig-
nals. Reliable analysis results are critical in heterogen-
eity analysis, because every false measurement would
immediately result in false categorization of a tumor as
“heterogeneous”. In a potential diagnostic setting, false
heterogeneity calling could even lead to the exclusion of
patients who could benefit from targeted therapy. To
systematically study molecular heterogeneity of gastric
cancer we further generated a new tissue microarray
(TMA) based platform. In this “heterogeneity TMA”
approach, a multitude of tissue cores are sampled per




A total of 113 gastric cancers treated by gastrectomy
and lymphadenectomy between 1995 and 2010 at theUniversity Medical Center Hamburg-Eppendorf, and
having at least one retained cancer containing tissue
block, were included in this study. The use of archived
diagnostic left-over tissues and their analysis for research
purposes (manufacturing of tissue microarrays) has been
approved by the local ethics committee (Ethics commis-
sion Hamburg, WF-049/09), and has been carried out in
compliance with the Helsinki Declaration. Informed
consent has not been collected specifically for the pa-
tient samples included in this study. This is in accord-
ance with local laws (HmbKHG, §12,1).
All tissues had been fixed in 4% buffered formalin and
were paraffin embedded. The average number of tumor
containing blocks was 3.7 (range: 1–9). Lymph node me-
tastases were identified in 61 of these patients. Among
these nodal positive patients, 24 had one, 7 had two, 13
had three, and 17 had more than three metastases. The
maximal number of metastases was 9. The patient age
ranged between 35 to 89 years (median 62 years). The
clinical and pathological features of our tumor collection
are provided in Additional file 1: Table S1.
Tissue microarray (TMA) construction
From the 113 primary tumors, 9 different tissue cylin-
ders were taken from tumor containing tissue blocks for
TMA manufacturing in order to obtain an optimal rep-
resentation of the entire tumor mass. Tissue blocks with
the highest tumor content were selected for TMA mak-
ing after careful histological revision of all archived tis-
sue blocks. Tissue blocks with small cancer areas (less
than approx. 2 mm2) were excluded from the study. If
less than 9 eligible tumor containing blocks were avail-
able from the primary tumor, multiple punches were
taken from one or several tumor blocks. Emphasis was
then placed on having a most representative sampling
with as equal as possible distances between the selected
cores and equal representation of all tumor foci. In
addition, a total of 435 tissue cores were taken from the
174 metastases of the 61 patients with metastatic dis-
ease, including 9 cores from the metastases of 37 pa-
tients, 6 cores from the metastases of 10 patients, and 3
cores from the metastases of 14 patients. On average,
there were 2.5 tissue cores (range 1–9) per metastasis,
including 3–9 cores per metastasis from the 24 patients
with one metastasis, 2–7 cores per metastasis from the 7
patients with 2 metastases, 3 cores per metastasis from
the 13 patients with 3 metastases, and 1–9 cores per me-
tastasis from the 17 patients with more than 3 metasta-
ses. TMA construction was performed as described
before [15]. In brief, hematoxylin and eosin (HE)-stained
sections were made from each block to define represen-
tative tumor regions. One tissue cylinder with a diameter
of 0.6 mm was then punched from each tumor “donor”
tissue block using a homemade semi-automated precision
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blocks. Four μm sections of the resulting TMA blocks
were transferred to an adhesive coated slide system
(Instrumedics Inc., Hackensack, NJ). Consecutive sections
were used for fluorescence in situ hybridization (FISH)
and immunohistochemistry (IHC).
Fluorescence in situ hybridization
Freshly cut TMA and conventional large sections were
used for FISH analysis. A commercial kit (paraffin pre-
treatment reagent kit 1, Abbott Laboratories, IL, USA)
was used for proteolytic slide pretreatment. Four differ-
ent probe sets were hybridized according to manufac-
turer’s instructions, including the PathVysion HER2/
CEP17 probe set (Abbott 02J01-030) for HER2 copy num-
ber detection, LSI EGFR Spectrum Orange/CEP7 Spectrum
Green probe set (Abbott Cat. # 05J48-001) for EGFR copy
number detection, LSI CCND1 Spectrum Orange/CEP11
Spectrum Green probe set (Abbott Cat. # 3N88-20) for
Cyclin D1 copy number detection, and the Zytolight
Spec c-Myc/Cen8 dual color probe (ZytoVision Cat. #
Z-2092-200) probe set for c-MYC detection. Prior to
hybridization, sections were deparaffinized, air-dried,
dehydrated and denatured for 5 minutes at 74°C in 70%
formamide-2x SSC (tri-sodium citrate sodium chloride)
solution. After overnight hybridization at 37°C in a humid
chamber, slides were washed and counterstained with
0.2 μmol/L DAPI (4′-6-diamidino-2-phenylindole) in anti-
fade solution.
Scoring of FISH signals
Each tumor spot was carefully visually evaluated, and
the predominant score, including gene and centromere
signal copy numbers as well as the gene-to-centromere
ratio, was recorded for each FISH probe in at least 20
non-overlapping cell nuclei. Data from our laboratory
have previously shown that diagnosis of amplification
based on signal number estimation is highly reliable
[16]. A tumor was considered amplified if at least twice
as much gene signals as compared to the corresponding
centromere signals were observed (ratio gene: centro-
mere ≥2.0). High-level amplification was considered if
more then 10 gene signals were counted. All other tu-
mors were considered non-amplified. Figure 1a-h gives
examples of amplified and non-amplified tumors.
HER2 immunohistochemistry
HER2 expression was analyzed using the HercepTest
(DAKO) according to the protocol of the manufacturer.
Antigen retrieval of the deparaffinized tissue sections
was performed in a water bath at 95°C to 99°C for 50 mi-
nutes followed by peroxidase blocking and incubation
with the prediluted primary antibody. Cell line test slides
provided by the manufacturer were used as positive andnegative controls. Immunostaining was scored following
a 4-step scale (0, 1+, 2+, 3+) according to the consensus
panel recommendations on HER-2 scoring for gastric
cancer [17]. Scores 0–1 were considered negative, scores
2–3 positive for HER2 expression. Examples of HER2
negative and HER2 positive immunostainings are given
in Figure 1i-l.
Assessment of heterogeneity
Only tumors with at least 3 interpretable tissue spots in
the primary cancers were included in heterogeneity ana-
lysis. A tumor was considered homogeneous for a given
marker (i.e., amplification of HER2, CCND1, EGFR, c-
MYC and expression of HER2) if all analyzable tissue
spots showed an identical result. All other tumors were
considered heterogeneous.
Large section validation
Three cases with suspicious heterogeneous findings on
the TMA (amplification in the metastases without amp-
lification in the primary tumor) were subjected to large
section analysis. In these cases, presence of tumor cells
was first verified in each spot by comparison of an H &
E stained consecutively cut reference section of the
TMA to validate heterogeneity. Conventional 4 μm large
sections were then cut from the corresponding cancer-
containing tissue blocks and subjected to FISH analysis
as described before.
Statistics
Chi2 test and contingency tables were used to compare
results of HER2 FISH and IHC analyses.
Results
Technical issues
For all patients data from primary tumors were only
included in our analysis if at least 3 of 9 cores had inter-
pretable data. Data from metastases were always in-
cluded, even if only one spot was interpretable as long
as the corresponding primary cancer was informative
with respect to this study. The rate of informative pri-
mary tumors (PT) and metastases (M) was 109 (PT) and
61 (M) for each of HER2, CCND1, c-MYC and EGFR
FISH, as well as HER2 IHC. Reasons for non-informative
results included non-interpretable FISH results due to
insufficient hybridization, a lack of unequivocal tumor
on certain spots and completely lacking spots on TMA
sections.
HER2 FISH
HER2 amplification according to our selected cut-off
(ratio ≥2.0) was observed in a total of 19 of 109 cancers
(17.4%). Sixteen of these patients (14.6%) had a high-


















Figure 1 Representative images of FISH- and IHC findings in gastric cancer. a-h) Examples of amplified and non-amplified cancers: a, b)
HER2, c, d) EGFR, e, f) CCND1 and g, h) MYC. i-l): Examples of HER2-immunohistochemistry negative (score 0–1, i, j) and positive (score 2–3, k, l)
cancers.
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signal clusters with a ratio ≥10.0 (11.0%). The relation-
ship between HER2 amplification and tumor pheno-
type is given in Additional file 1: Table S1. As expected
from earlier studies, HER2 amplification was more fre-
quent in intestinal tumors (16%) as compared to dif-
fuse cancers (5%). Significant associations between
HER2 amplification and tumor stage, grade or nodal
stage were not found in our small set of only 109 can-
cers. Detailed spot by spot information on each of the
19 patients with at least one amplified tissue sample is
given in Figure 2. Ten of these 19 patients showed
homogeneous HER2 amplification in all analyzed samples
even though the level of amplification varied somewhat
from area to area. Three of the nine patients with heteroge-
neous amplification had heterogeneous findings in the pri-
mary tumor that involved high-level amplification (cases
#14, #15 and #16). One additional cancer with heterogen-
eity within the primary tumor (case #17) had a low-level
amplification in some but not all spots. Notably, none of
these heterogeneously low-level amplified samples had adetectable HER2 overexpression by IHC. Remarkably,
there were four amplified tumors cases (#11, #12, #18, #19)
that showed high-level amplification in metastases only.
Large section validation analysis in three of these cases
(#11, #12, and #19) confirmed the high-level amplifications
in the metastases of cases #11 and #12, but found case #19
non-amplified. Heterogeneity within the same metastasis,
i.e. spots with low-level amplification and spots without
amplification in the same metastasis, were not found.
HER-2 IHC
Positive HER-2 staining with a strong or intermediate
circumferential membrane immunostaining (2+ and 3+)
was found in 16 of 109 gastric cancers (14.7%). On a
spot-by-spot basis, HER-2 expression was strongly linked
to HER-2 amplification (Table 1, p < 0.0001). In general,
HER2 IHC suggested more heterogeneity in gastric can-
cer than FISH. Only 5 patients had a 3+ or 2+ IHC re-
sult in all evaluable samples. These 5 patients had also
homogeneous HER2 amplification. Four other cancers
(cases #2, #3, #5, and #6) with homogeneous HER2
Figure 2 HER2 FISH and IHC findings in primary gastric cancers and their metastases in 19 cancers with HER2 amplification. a“Tumor”
indicates the cases number referred to in the text. bThe FISH and IHC results of individual tissue spots are indicated by integers reflecting the
copy numbers of centromere 17/HER2 (i.e. 2/20, black face) and the HercepTest IHC score (i.e. 3, white face) in the primary and metastases spots.
Green color in the primary/metastases spots area indicates high-level HER2 amplification or positive IHC findings, orange color indicates low-level
amplification, and blue color indicates negative IHC findings. cBold black outline in the “metastases spots” highlights spots that were derived
from the same metastasis. d“Heterogeneity” indicates whether FISH or IHC findings were homogeneous (Homo.) or heterogeneous (Hetero).
e“Validation” shown the large section FISH results in 3 cases obtained from the primary cancer (case #11 and #19) and from the amplified
metastasis (#12).
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one or several HER2 IHC negative (0/1+) spots. Within
the group of 9 “FISH heterogeneous” cases, heterogen-
eity was also seen by IHC in 7 cancers, while the other 2
cancers were homogeneously IHC negative. While these
2 cases had only low-level amplification, IHC negativity
also included 3 spots with high-level amplification (case
#10). Heterogeneity within the same metastasis wasTable 1 Association between HER2 FISH and IHC findings
in 1,248 tissue spots obtained from 109 gastric cancers
HER2 FISH n
HER2 IHC (%) p-value
0 1+ 2+ 3+
Amplification 150 7.3 14.0 16.7 62.0
<0.0001
No amplification 1098 80.5 17.4 1.6 0.5found in two cases (#2, #13), which showed a discrepant
IHC result in one out of three metastases spots each.
EGFR FISH
EGFR amplification was observed in 7 cancers (6.4%).
All amplified cases had high-level amplifications with
≥10 EGFR copies per tumor and showed large EGFR
gene signal clusters. Detailed spot by spot information
on each of the 7 patients with at least one amplified tis-
sue sample is given in Figure 3. The relationship be-
tween EGFR amplification and tumor phenotype is given
in Additional file 2: Table S2. Significant associations be-
tween EGFR amplification and tumor stage, grade, nodal
stage, or histological subtype were not found in our
small set of only 109 cancers. Only 2 of 7 amplified cases
showed a homogeneous amplification pattern. The other
Figure 3 EGFR FISH findings in primary gastric cancers and their metastases in 7 cancers with EGFR amplification. a“Tumor” indicates
the cases number referred to in the text. bThe FISH results of individual tissue spots are indicated by integers reflecting the copy numbers of
centromere 7/EGFR (i.e. 2/20, black face) in the primary and metastases spots. Green color in the primary/metastases spots area indicates
high-level EGFR amplification, and blue color indicates negative IHC findings. cBold black outline in the “metastases spots” highlights spots that
were derived from the same metastasis.
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tumor. In 3 cancers with metastases, two had an identi-
cal result in all analyzable metastases. The remaining
case (#11) had one metastasis with high-level amplifica-
tion and two metastases with normal FISH findings.
Heterogeneity of EGFR amplification within the same
metastasis was not observed.
CCND1 FISH
CCND1 amplification was observed in 19 of 109 gastric
cancers (17.4%). Ten amplified cases showed high-level
gene amplification (≥10 CCND1 signals per cancer cell),
including 5 cancers (#21, #25, #26, #28, #31) with large
CCND1 gene signal clusters. There was no obvious associ-
ation with tumor phenotype (Additional file 2: Table S2).
Detailed information on amplified cases is given in
Figure 4. Nine of 17 cancers considered amplified in
the primary cancer showed homogeneous amplification.
This rate was even higher for cancers with high-level amp-
lification (7 of 9). In contrast, only 3 of 10 cancers with a
heterogeneous amplification pattern in the primary cancer
had spots with high-level amplification. There were two
cases with amplification only seen in the nodal metastases
(cases #2 and #33). These tumors had a borderline finding
in the metastases with 2 centromeres and 4 CCND1 sig-
nals per tumor cell. Such borderline findings were also the
reason for heterogeneity within the same metastasis that
was observed in 3 cases (#2, #33, #13).
MYC FISH
MYC amplification was observed in 27 of 109 gastric
cancers (24.8%). Only 10 (37%) amplified cases showed
high-level gene amplification (≥10 MYC signals per can-
cer cell), including 4 cancers (#21, #40, #41, #43) with
large MYC gene signal clusters. MYC amplification was
significantly linked to intestinal tumors (p = 0.0333).
There was no obvious association with tumor phenotypein our set of 109 cancers (Figure 5). Detailed information
on amplified cases is given in Figure 4. MYC amplifica-
tion was typically heterogeneous (23/27 amplified cases,
85%). Presence of heterogeneity was most prevalent in
cases with low-level amplification: heterogeneous ampli-
fication was found in all (100%) 17 cases with low-level
amplification, but only in 6 of 10 (60%) cases with high-
level amplification. One of these cancers (#40) had one
high-level amplified metastasis and one non-amplified
metastasis. The 17 cases with heterogeneous low-level
amplification included 8 tumors that had only borderline
amplification findings (2–3 centromere and 4–6 MYC
signals). Heterogeneity within the same metastasis was
observed in 7 cases, but was always caused by borderline
findings.
Co-amplification patterns
Unequivocal co-amplifications involving high-level ampli-
fication of at least two of the four genes were found in 8
tumors (Figure 6), including co-amplification of HER2
and EGFR or MYC in 2 cases each, and co-amplifications
of EGFR/CCND1, EGFR MYC, CCND1/MYC, and
EGFR/MYC/CCND1 in one case each. One case (#11)
showed amplification of HER2 and EGFR in different
metastases, and had no HER2/EGFR co-amplified pri-
mary cancer spots.
Discussion
Diagnostic accuracy of a molecular assay may be limited
if the analyzed biomarker is only present in a fraction of
a tumor. Absence of a drug target structure in a cancer
subpopulation of a patient tested “positive” for a specific
drug target may cause drug resistance after outgrowth of
the target-negative population under therapy. Consider-
ing its importance, the number of studies systematically
analyzing target heterogeneity in cancer is relatively
small. Even studies addressing the issue of tumor
Figure 4 CCND1 FISH findings in primary gastric cancers and their metastases in 19 cancers with CCND1 amplification. a“Tumor”
indicates the cases number referred to in the text. bThe FISH results of individual tissue spots are indicated by integers reflecting the copy
numbers of centromere 11/CCND1 (i.e. 2/20, black face) in the primary and metastases spots. Green color in the primary/metastases spots area
indicates high-level CCND1 amplification, and blue color indicates negative IHC findings. cBold black outline in the “metastases spots” highlights
spots that were derived from the same metastasis.
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one slide/block per tumor/patient. However, one tissue
section may not completely represent the biology of a
large cancer. “Heterogeneity TMAs” were thus manufac-
tured by our group as new tools for studying molecular
cancer heterogeneity [18]. A TMA analysis of one sam-
ple each from nine different cancer areas obtained from
up to nine different blocks distributed across the entire
tumor enables a comprehensive three-dimensional high-
throughput analysis of molecular features in large series
of tumors. The heterogeneity TMA concept introduced
here differs markedly from previous attempts to increase
the representation of prostate cancer in TMAs by sam-
pling multiple cores from just one tumor block [19,20].
The data of our study demonstrate that heterogeneity of
the analyzed amplification occurs in relevant fractions of
gastric cancers. Finding substantial off/on heterogeneity
for four of four analyzed genes suggests that molecular
heterogeneity is rather a rule than an exception for bio-
markers in gastric cancer. This clearly limits the poten-
tial of treatment decisions based on the amplification
status determined on one single clinical cancer biopsy.
HER2 was found amplified in 19 of 109 (17.4%) can-
cers, including 16 cancers with 3+ positivity by IHC at
least in one TMA spot. These data fit well with earlierstudies reporting HER2 amplification in 10-27% [21-25]
and HER2 overexpression in 5-53% [24-28]. HER2 was
the gene with highest homogeneity of amplification in
this study. Ten of 12 cancers with large HER-2 gene sig-
nal clusters found in the primary cancer had homoge-
neous amplification in the entire primary tumor and in
all corresponding metastases. This is also consistent with
an earlier observation by our group where we found
homogeneity of HER2 amplification in 8 of 8 amplified
cancers using a different approach. In contrast to our
current study, where we systematically sampled all can-
cers across their entire tumor mass, we had earlier ana-
lyzed only one 0.6 mm core per patient and validated
the HER2 status on all available tissue blocks of “posi-
tive” patients by large section analysis [24]. Our earlier
study thus suffered from the potential drawback that the
initial screening would enrich for tumors with large
HER2 positive areas, and that cancers with HER2 nega-
tive status on one 0.6 mm spot were not validated to ex-
clude small HER2 positive cancer areas. The nearly
identical findings by two very different but rather sys-
tematic approaches corroborate the assumption that the
HER2 status is fairly homogeneous in gastric cancer.
Clinically, this notion is also supported by the obvious
success of trastuzumab therapy in the treatment of
Figure 5 MYC FISH findings in primary gastric cancers and their metastases in 27 cancers with MYC amplification. a“Tumor” indicates
the cases number referred to in the text. bThe FISH results of individual tissue spots are indicated by integers reflecting the copy numbers of
centromere 8/MYC (i.e. 2/20, black face) in the primary and metastases spots. Green color in the primary/metastases spots area indicates high-level
MYC amplification, and blue color indicates negative IHC findings. cBold black outline in the “metastases spots” highlights spots that were derived
from the same metastasis.
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ity is usually determined on one small piece of tissue
only. Other authors had recently reported heterogeneous
HER2 findings in 23-79% of HER2 overexpressing or
amplified gastric cancers [29-33]. This includes two
studies describing HER2 positive nodal metastases in
case of HER2 negative primary cancers [26,32]. It is
noteworthy, that four such cases were also found in our
series. We attribute this phenomenon to small un-
detected HER2 amplified sub-clones in the primary can-
cer, as the entire tumor mass cannot be paraffin
embedded, retained, and molecularly analyzed in case of
large cancers. The high number of such cases raises the
question whether a positive HER2 status could indeed
facilitate metastasis in gastric cancer. It is further of
note, that most metastases were HER2 negative – as the
primary cancer – in these patients. This potentiallylimits the clinical relevance of these HER2 positive
metastases.
The interrelation of FISH and IHC data highlights im-
portant biological and technical issues related to HER2
in gastric cancer. Technically it is of note, that HER2
IHC results can be influenced by pre-analytical factors
such as fixation [13]. Too short fixation results in etha-
nol exposure of unfixed tissue during tissue processing
(dehydration) and can lead to false positive results
[34,35]. Prolonged formalin fixation can result in re-
duced sensitivity of HER2 IHC [36,37]. Biologically,
there may be two distinctively different groups of “HER2
positive gastric cancers”. First, there is a fraction of can-
cers with a massive increase of HER2 signals, which is
caused by an intrachromosomal amplification of small
stretches of DNA resulting in a clustered arrangement
of HER2 FISH signals. These cases have a very high
Figure 6 Comparison of the FISH finding in 8 tumors showing high-level co-amplification of at least 2 of the 4 analyzed genes.
a“Tumor” indicates the cases number referred to in the text. bGreen color in the primary/metastases spots area indicates high-level amplification,
orange color indicates low-level amplification, and blue color indicates negative findings. cBold black outline in the “metastases spots” highlights
spots that were derived from the same metastasis.
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irrespective of some variability in tissue fixation. These
cancers often have a homogeneous distribution of ampli-
fication and perhaps there is a preference of amplified
cancer cells to metastasize. We consider the few samples
with negative HER2 IHC in homogeneously amplified
cancers as IHC artifacts. Second, there is another group
of cancer with a low-level increase of HER2 genes obvi-
ously resulting in lower levels of protein overexpression
challenging the potential of IHC for reliable detection in
a clinical setting. The high rate of discordant IHC/FISH
results in this group is thus not surprising. Most of these
“amplifications” involve longer stretches of DNA and re-
sult from duplications and other rearrangements leading
to a more even – non-clustered – arrangement of HER2
signals. Despite attempts to acknowledge the borderline
nature of some of these findings by introducing a “bor-
derline” group in the ASCO guidelines for HER2 meas-
urement in breast cancer [38], it is still unclear to what
extent these tumors respond to anti-HER2 therapy.
EGFR was found amplified in 7 of 109 cancers (6.4%)
in at least one TMA spot. These data fit very well with
earlier studies reporting EGFR amplification in 4.9-8.6%
by southern blotting [39,40], 7.7-13% by array-based
copy number assays [41,42], and 2–6.9% by FISH in lar-
ger studies [29]. Higher amplification rates (17-20%)
were only reported from small FISH studies analyzing70–80 cancers [43]. We did not find statistically signifi-
cant associations between the EGFR amplification status
and gastric cancer phenotype in our study, which is at
least to a large extent expected due to the small number
of amplified cancers. Some earlier studies analyzing 82–
511 gastric cancers linked EGFR amplification to ad-
vanced and undifferentiated cancers [44] and poor prog-
nosis [45]. EGFR amplification may be of relevance to
gastric cancer as a multitude of drugs exists that target
EGFR. Four clinical trials had recently not found a sur-
vival benefit of gastric cancers treated by standard
chemotherapy plus anti-EGFR drugs [46-49], and a
retrospective EGFR analysis did not reveal significant as-
sociations between the immunohistochemical EGFR ex-
pression levels and therapy response or patient survival
[48]. However, the vast majority of cancers showed low-
level staining according to the various different scoring
criteria used in these studies. Given the rarity of high-
level EGFR amplification in gastric cancers, a benefit of
amplified patients from cetuximab could have potentially
been missed. In a recent preclinical study, 4 of 20 gastric
cancer xenografts responded favorably to the anti-EGFR
antibody cetuximab, two of which had EGFR amplifica-
tion [50]. A potential benefit of EGFR amplified gastric
cancers to anti-EGFR therapies deserves further evaluation
in which, however, the frequent heterogeneity of amplifica-
tion – 5/7 EGFR amplifications were heterogeneous in our
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phase III trial investigating the addition of nimotuzumab
(a monoclonal antibody to EGF), to irinotecan as second
line treatment of EGFR overexpressing gastric cancers
is now ongoing (ENRICH, ClinicalTrials.gov identifier
NCT01813253). Hopefully, the selection of EGFR-
positive cancers will enrich for patients who will bene-
fit from anti EGFR therapy.
CCND1 was found amplified in 19 of 109 (17.4%) gas-
tric cancers, including 10 (9.2%) cancers with high-level
amplification. This is again in the range of previous
studies reporting CCND1 amplification in 17% by south-
ern blot [51], 10% by array-CGH [42] and in 3-10% by
FISH [29,52]. CCND1 showed almost the same level of
homogeneity of amplification in this study as HER2,
with 9 of 19 amplified cases showing amplification of all
spots from the primary and metastatic sites. That seven
of 10 cases with high-level amplification had a homoge-
neous FISH result suggests that CCND1 amplification
might often represent an early event during tumor de-
velopment. This is also supported by the fact that we did
not find an association between CCND1 amplification
and pathological tumor features or histological subtype,
which is in concordance with earlier studies on CCND1
amplification or expression in gastric cancer [53]. Of
note, Kim et al. [54] reported an association between al-
cohol consumption and CCND1 amplification in gastric
cancer patients, suggesting a specific environmental fac-
tor for cancer initiation. Amplification of CCND1 may
have potential clinical impact in gastric cancer for two
reasons. First, CCND1 amplification has been linked to
resistance to the EGFR inhibitor gefitinib in experimen-
tal models of head & neck cancer [55], raising the possi-
bility that it might also negatively impact the efficacy of
potential anti-EGFR therapy in gastric cancer. Second,
several compounds against the CCND1 associated
cyclin-dependent kinase CDK4 are currently under in-
vestigation in clinical phase I-II trials in multiple cancer
types, including an open-label phase I study on advanced
solid cancers (NCT01188252) assessing of the impact of
CCND1 amplification and expression on therapy effi-
cacy. It will be interesting to see whether CCND1 ampli-
fication will turn out as a predictor of response or
resistance to such drugs.
MYC was the most frequently amplified gene in our
study, with 27 of 109 (24.8%) cancers showing MYC
amplification in at least one tumor spot. These numbers
are in the upper range of results reported from previous
studies finding MYC amplification in 4-26% by southern
blot [56-58], 4-30% by array-based or conventional com-
parative genomic hybridization analysis [42], and 1.3-
7.9% by FISH [29,59]. Markedly, higher rates was only
reported from two small studies finding MYC amplifica-
tion in 3 of 7 gastric cancers by FISH [60] and in 17 of33 tumors using less quantitative PCR for CCND1 amp-
lification analysis [61]. The comparatively high amplifi-
cation rate found by FISH analysis in our study might
have two reasons. First, it is obvious that the analysis of
multiple tissue spots from different tumor areas has a
higher likelihood to detect amplification in a heteroge-
neous cancer as if only one sample is analyzed. In fact,
MYC amplification showed the highest degree of hetero-
geneity among the four genes analyzed in our study. Sec-
ond, most amplifications (i.e., 17 of 27, 63%) were low-
level with borderline ratios resulting from 4–6 gene cop-
ies and 2–3 centromere copies. Such findings are prone
to inter-observer variations even by FISH analysis and it
is likely, that the cut-off level of 2.0 for definition of
amplification is at least reached once if multiple counts
of multiple areas are executed. This is also reflected in
our data, since all 17 cases with low-level MYC amplifi-
cation identified in our study were considered heteroge-
neous only because of minute copy number variations. It
is likely that such low-level amplification is often not
MYC specific, but may result from gross chromosomal
gains of 8q that belong to the most frequent alterations
in gastric cancers [62]. A high fraction of low-level MYC
gains in gastric cancers is also confirmed by Suzuki et al.
who reported a relative gain (ratio 1.1-1.9) in all of 21
gastric cancers analyzed by MYC-FISH [63]. In contrast,
high-level amplification, as indicated by presence of
large signal clusters containing more than 10 MYC cop-
ies, were found only in 9% of our gastric cancers. All but
one of these cancers had areas with and without clear-
cut high level amplification or even areas with normal
MYC copy numbers, suggesting that high-level MYC
amplification occurs at later stages of gastric cancer pro-
gression. Finding a significantly higher rate of MYC
amplification in intestinal as compared to diffuse cancers
suggests a role of MYC for progression of intestinal
cancers.
Analyzing four different genes in the same set of 109
cancers allowed us to draw conclusions on the co-
amplification patterns of these genes. While on a patient
basis, co-amplification of all these genes occurred at fre-
quencies that are compatible with incidental co-
alterations, there was one case that showed mutual ex-
clusive amplification HER2 and EGFR in the different
tissue spots in the primary tumor and in two metastases.
Since HER2 and EGFR receptors activate the same sig-
naling cascades, the finding of mutual exclusive amplifi-
cation indicates that alteration of either gene is sufficient
for gastric cancer cells, and that different subclones of
the tumor may have developed HER2 and EGFR amplifi-
cation independently from each other. Similar conclu-
sion were made by Deng et al. [41] who found copy
number alterations of HER2 and EGFR to be restricted
to different subsets of gastric cancers. Finding both
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same cancer, however, might provide an explanation for
failure of anti-Her2 therapy in some cases. Dual-specific
HER2 and EGFR inhibitors like lapatinib may be more
effective than single agents in such cases, but may re-
quire analysis of multiple tumor areas.
The results of our study underline the importance of
taking multiple (6–8) biopsies from different tumor
areas for diagnostic purposes as suggested in the guide-
lines for endoscopic biopsy for evaluation of predictive
parameters [64]. This might be particularly important
when a highly heterogeneous target gene is analyzed.
The example of MYC amplification shows that only
small parts of a cancer may harbor such alterations, and
that MYC amplification may be present only in as little
as two of the nine analyzed cancer regions. It cannot be
excluded, however, that more cases with MYC amplifica-
tion would have been identified if more than 9 cancer
spots were analyzed. Of note, findings obtained from
small TMA cores (0.6 mm) are not fully interchangeable
with clinical biopsies, which typically include a larger
amount of tissue. Nevertheless, in case of analyzing
intratumoral heterogeneity, the size of the analyzed tis-
sue sample may be less important than sampling from
different areas. From a practical point of view, it does
not seem to be possible to fully avoid a sampling bias
unless the entire tumor has been removed and becomes
available for molecular analyses. However, the compara-
tively low degree of HER2 heterogeneity suggests that
currently recommended endoscopic sampling strategies
with 6–8 biopsies makes it unlikely that this alteration
will be missed when present.
In summary, the results of our study demonstrate
intra-tumor heterogeneity in 50-80% of the analyzed pri-
mary cancers for the 4 analyzed genes. Although “het-
erogeneity” was often caused by minute copy number
changes resulting in a switch of the diagnostic criteria
from “amplified” to “non-amplified” without obvious
biological differences, there was also substantial hetero-
geneity resulting from parallel existence of high-level
amplified subclones and those with normal copy num-
bers. Such “on-off” heterogeneity was frequently found
for MYC and EGFR, but rarely for HER2. Tumors har-
boring multiple subclones with alterations of different
therapy target genes are rare but represent an existing
category which may open new therapy options based on
refined molecular analyses of multiple tumor areas opti-
mally also including metastases.
Conclusions
Heterogeneity is common for the biomarkers HER2,
CCND1, EGFR and MYC in gastric cancer and may
therefore limit treatment decisions based on the analysis
of a single clinical biopsy.Additional files
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